Kristen Belmonte Slaoui
Head of Business Development

Kristen Belmonte Slaoui joined Stiefel, a GSK company, in March 2010 as Director of Business Development and Licensing. Prior to her current role, she was part of the GSK Corporate Development Team where she led acquisition of Stiefel in 2009.

Kristen spent several years in GSK’s Worldwide Business Development team leading Business Development & Licensing efforts in Immuno-inflammation. During this time, she was responsible for closing several significant deals for GSK, such as those with Genmab (Arzerra™), Tolerx (Toliva™), Cellzome, Regulus and Dynavax, and the acquisition of Praecis.

Kristen also has six years experience in drug discovery in Neuroscience at Merck Research Laboratories and in the Respiratory CEDD (Center of Excellence in Drug Discovery) at GSK.

She holds a Doctoral degree in Physiology from The Johns Hopkins University Bloomberg School of Public Health, where she has been an adjunct assistant professor since 2001. She completed postdoctoral studies in Neuroscience (Ophthalmology) at the University of Washington in Seattle, and is the author of more than 40 original publications and patents.

«Back to Stiefel Leadership Team